<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670095</url>
  </required_header>
  <id_info>
    <org_study_id>17773A</org_study_id>
    <nct_id>NCT03670095</nct_id>
  </id_info>
  <brief_title>Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions</brief_title>
  <official_title>Interventional, Randomized, Single-dose, Open-label, Crossover, Bioequivalence Study in Healthy Subjects to Compare Two Pharmaceutical Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the release of memantine into the bloodstream of
      two different formulations: one formulation containing lactose and one without lactose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two cohorts: A1 and A2.

      Subjects in Cohort A1 will be administered the investigational medicinal product (IMP) in a
      fasted state and subjects in Cohort A2 will be administered the IMP in a fed state.

      Each subject will change cohort during study participation, so that dosing will be done over
      two periods: either first fed and then fasted, or first fasted and then fed. The two periods
      will be separated by a period of 28 days (+7 days) where no investigational medicinal product
      is given.

      All subjects will be confined to the clinic from one day prior to dosing until Day 4 (72
      hours post-dose) in each dosing period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Actual">December 24, 2018</completion_date>
  <primary_completion_date type="Actual">December 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-72h in fed state for test and reference treatment</measure>
    <time_frame>From zero to 72 hours post dose</time_frame>
    <description>Area under the memantine plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72h in fasted state for test and reference treatment</measure>
    <time_frame>From zero to 72 hours post dose</time_frame>
    <description>Area under the memantine plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of memantine in fed state for test and reference treatment</measure>
    <time_frame>From zero to 72 hours post dose</time_frame>
    <description>Maximum observed plasma concentration of memantine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of memantine in fasted state for test and reference treatment</measure>
    <time_frame>From zero to 72 hours post dose</time_frame>
    <description>Maximum observed plasma concentration of memantine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax in fed state for test and reference treatment</measure>
    <time_frame>From zero to 72 hours post dose</time_frame>
    <description>Nominal time corresponding to the occurrence of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax in fasted state for test and reference treatment</measure>
    <time_frame>From zero to 72 hours post dose</time_frame>
    <description>Nominal time corresponding to the occurrence of Cmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lactose-free memantine tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(treatment A - test) - 10 mg; orally as a single dose in fed and fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose-containing memantine tablet (Ebixa®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose-free memantine</intervention_name>
    <description>Lactose-free memantine tablet, 10 mg; orally as a single dose</description>
    <arm_group_label>Lactose-free memantine tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Lactose-containing memantine tablet, 10 mg, orally as a single dose</description>
    <arm_group_label>Lactose-containing memantine tablet (Ebixa®)</arm_group_label>
    <other_name>Ebixa®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women ≥18 years of age with a body mass index (BMI) ≥18.5 and ≤28
             kg/m2.

          -  Women must be non-pregnant and non-lactating.

        Exclusion Criteria:

        - The subject has any concurrent disorder that may affect the particular target or
        absorption, distribution, or elimination of the IMP.

        Other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shuguang Hospital, Shanghai TCM University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

